Total Utang marang Modal American Oncology Network (AONC)

American Oncology Network - logo grafis emiten AONC

This price visualization for American Oncology Network (AONC) debt load is at 0.00, highlighting the risks of narrow specialization in US regional centers and attempts to optimize profits through pharmacy digitalization. The business relies on a steady patient inflow, guaranteeing predictable revenue. Meanwhile, American Oncology Network (AONC) delegates its IT infrastructure and accounting to external contractors while maintaining direct control over its medical staff.

American Oncology Network Inc (AONC): Rasio Utang marang Ekuitas saka 21.02.2024 nganti 04.08.2024
Produk dadi American Oncology Network Inc

American Oncology Network leverages its regional clinic dominance and procurement pricing power to effectively manage margins. By analyzing the trend of the company's total liabilities-to-equity ratio, an investor assesses the business's leverage by comparing total debt with equity, which determines the financial stability and debt load risk for this asset class.

Analisis pesaing American Oncology Network

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Total Utang marang Modal CSBR|Total Utang marang Modal xbiotech.com (XBIT)|Utang marang Ekuitas CEL-SCI CVM|OSTX - Rasio Total Utang marang Ekuitas|Radiopharm Theranostics Limited - Total Utang marang Modal|Utang marang Modal Artiva Biotherapeutics, Inc.|adlainortye.com (ANL) - Utang marang Ekuitas|verupharma.com - Rasio Kabeh Utang marang Dana Pribadi|TPST (Tempest Therapeutics, Inc.) - Total Utang marang Modal|Xilio (XLO) - Koefisien Total Utang marang Modal|Total Utang marang Modal RENB|Rasio Total Utang marang Ekuitas muraloncology.com MURA|Total Utang marang Modal KAPA (Kairos Pharma)|Total Utang marang Modal OnKure Therapeutics, Inc. OKUR|GDTC - Utang marang Ekuitas|CRIS (Curis, Inc.) - Rasio Utang marang Ekuitas|APLM (apollomicsinc.com) - Rasio Total Utang marang Ekuitas|Tharimmune Corporation - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Advanced Biomed Inc.|Utang marang Modal genprex.com GNPX|Utang marang Ekuitas Calidi Biotherapeutics (CLDI)|Sunshine Biopharma Inc. - Rasio Utang marang Ekuitas|Total Utang marang Modal XBIO (Xenetic Biosciences, Inc.)|SLRX - Rasio Total Utang marang Ekuitas|PPBT - Utang marang Ekuitas|Utang marang Modal beigene.com|Checkpoint Therapeutics, Inc. (CKPT) - Utang marang Ekuitas|ELEV (elevationoncology.com) - Utang marang Ekuitas|Utang marang Ekuitas iCAD Inc.|Utang marang Modal Ikena IKNA|Total Utang marang Modal NTBL|viracta.com (VIRX) - Rasio Utang marang Modal|MorphoSys - Rasio Total Utang marang Ekuitas|NAYA Biosciences Inc (NAYA) - Utang marang Modal|AAPGV: Rasio Total Utang marang Ekuitas